The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry
French biotech company Nūmi has secured €3.7 million in non-dilutive funding through the France 2030 i-Démo programme to support the development and scale-up of its human milk bioactive technology.
The company has been selected as an i-Démo laureate, with the funding set to support the scale-up of its bioprocess, development of its next generation of human milk bioactives and preparations for industrialisation.
Nūmi is developing a biomanufacturing platform that uses mammary cells to produce bioactive ingredients naturally found in human milk.
According to co-founder and CEO Eden Banon-Lagrange, the award represents recognition of the technology the company has been developing over the past three years.
“This funding will help us push the technology further, from scaling our bioprocess to advancing our next generation of human milk bioactives and preparing for industrialisation,” Banon-Lagrange said.
The company indicated that further announcements are expected in the coming weeks.
